CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled / 12 target
Drug / intervention
AGN-Cogni.Qdrug
Likely dose
800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05375539
NCT05375539Phase 1CompletedUpdate Overdue (0.3/mo)Completion was 16mo ago
CompareCT.gov

Angelica Herbal Supplement AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics (PK) Dose-Response in Prostate Cancer Patients (PK Dose Trial)

Milton S. Hershey Medical Center·interventional·Posted May 16, 2022·Updated Jun 2, 2026

In Brief

A Phase 1 clinical trial evaluating AGN-Cogni.Q for Prostate Cancer. Completed, enrolled 12 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

This study is to obtain acute dose safety and pharmacokinetics/pharmacodynamics (PK/PD) data in a dose-response trial in prostate cancer patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedMay 16, 2022
Enrollment StartMay 2, 2023
Primary CompletionFeb 15, 2025
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.1 years ago

Arms & Interventions

AGN-Cogni.Qexperimental

Dose level +1 (800 mg, 4 Cogni.Q capsules, Fast at least 2 h before dose and 1 h after) Dose level +2 (1,200 mg, 6 Cogni.Q capsules, Fast at least 2 h before dose and 1 h after) Dose level +3 (1,600 mg, 8 Cogni.Q capsules, Fast at least 2 h before dose and 1 h after)

Drug: AGN-Cogni.Q

Interventions

AGN-Cogni.Qdrug

Herbal dietary supplement products containing/based on AGN alcoholic extracts (including CognI.Q; Decursinol-50TM, GWB78®, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) are marketed in the US for memory enhancement, pain relief and for women's post-menopausal symptom management.